NCT06918145Enrolling by invitation
Clinical Study on Lymphaticovenous Anastomosis（LVA） for the Treatment of Alzheimer's Disease（AD）
Clinical Study on the Safety, Efficacy, and Mechanisms of Lymphaticovenous Anastomosis (LVA) for the Treatment of Alzheimer's Disease (AD)
Source: ClinicalTrials.gov · Last updated 9 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to explore the safety and efficacy of Lymphaticovenous Anastomosis (LVA) for the Treatment of Alzheimer's Disease (AD). The main questions it aims to answer are: 1. After LVA surgery treatment, do patients with AD show improvement in dementia, cognitive impairment, neurobehavioral symptoms? 2. What are the complications associated with LVA treatment for AD, including perioperative complications and long-term complications? 3. What is the mechanism of LVA treatment for AD patients, and what changes occur in AD-related biomarkers (Aβ42、 Aβ40、Aβ42/40、pTau217、pTau181) before and after surgery?
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 23 Mar 2025
- Start date
- 2 Apr 2025
- Primary completion date
- 1 Mar 2030
- Lead sponsor
- Peking University Third Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT06918145
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 2 Apr 2025 to the primary completion date, 1 Mar 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Poor overall health, unable to tolerate surgery;
Other illness
- Presence of other neurological or psychiatric disorders;
- Severe bleeding tendency due to coagulopathy;
- Other conditions that preclude tolerance to surgery.
Other
- Preoperative anesthetic assessment indicates inability to tolerate general anesthesia;
- Inability to comply with treatment and follow-up;
Who the study is looking for
- Patients diagnosed with Alzheimer's Disease based on biomarkers, imaging, and clinical symptoms;
- Male or female aged 50-85 years (inclusive);
- At least one caregiver who can live with the patient for an extended period;
- No severe systemic diseases affecting the heart, liver, kidneys, etc.;
- Patients who voluntarily participate in clinical recruitment, accept the LVA surgical treatment plan, and sign the informed consent form.
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Third Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.